Allogene Therapeutics/$ALLO
1D1W1MYTD1Y5YMAX
Capital at risk
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Ticker
- $ALLO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 151
- Headquarters
- South San Francisco, United States
- Website
- allogene.com
ALLO Metrics
BasicAdvanced
$577M
-
-$0.65
0.47
-
Price and volume
Market cap
$577M
Beta
0.47
52-week high
$4.46
52-week low
$1.04
Average daily volume
5.5M
Financial strength
Current ratio
10.716
Quick ratio
10.553
Long term debt to equity
0.161
Total debt to equity
0.181
Interest coverage (TTM)
-138.71%
Profitability
EBITDA (TTM)
-168.649
Gross margin (TTM)
-2,540.52%
Net profit margin (TTM)
-3,566.68%
Operating margin (TTM)
-3,886.14%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-22.08%
Return on equity (TTM)
-42.39%
Valuation
Price to revenue (TTM)
91.592
Price to book
1.32
Price to tangible book (TTM)
1.32
Price to free cash flow (TTM)
-4.142
Free cash flow yield (TTM)
-24.14%
Free cash flow per share (TTM)
-0.403
Growth
Earnings per share change (TTM)
-41.36%
3-year revenue growth (CAGR)
323.70%
3-year earnings per share growth (CAGR)
-36.34%
What the Analysts think about ALLO
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
Analyst projections of the future price of Allogene Therapeutics stock.
Bulls say / Bears say
Cema-cel produced MRD negativity in 58.3% of patients versus 16.7% with observation in the interim ALPHA3 analysis. The FDA’s RMAT and Fast Track designations add regulatory support to the programme, although they are not approval. (GlobeNewswire)
ALPHA3 site activation reached more than 80 centres about six months ahead of plan, with roughly 100 expected by year-end. That supports the case that an off-the-shelf treatment could be delivered more easily in community settings than patient-specific CAR T. (BioSpace, The Motley Fool)
ALLO-329 gives Allogene a second potential value driver in autoimmune disease. Enrollment in the Phase 1 RESOLUTION trial is progressing across dose levels and lymphodepletion strategies, with clinical and translational data expected in the fourth quarter of 2026. (BioSpace, The Motley Fool)
The encouraging ALPHA3 result is based on only 12 treated patients versus 12 observed patients, and MRD clearance is not the trial’s primary endpoint. Event-free survival remains blinded, with the interim analysis due in mid-2027 and the primary readout in mid-2028. (GlobeNewswire, EarningsCalls.dev)
ALLO-316 showed a 31% confirmed response rate in CD70-high renal cell carcinoma under the optimised regimen, but the dataset is small and management acknowledged real safety challenges. That makes the solid-tumour programme a less certain support for the valuation. (The Motley Fool)
Allogene remains pre-commercial and loss-making, so shareholders have already paid for additional runway through a $200.4 million public offering. June-end cash and investments of $423.6 million may fund operations into 2029, but the financing increased dilution while the company waits for its pivotal readouts. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.
ALLO Financial Performance
Revenues and expenses
ALLO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALLO News
AllArticlesVideos
Funds containing ALLO
AllUSDGBPEUR
Fund name | Fund size | $ALLO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.